Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...
Merck Touts Phase 3 Success For $20B Cancer Drug Keytruda In Untreated Head And Neck Cancer Patients
On Tuesday, Merck & Co Inc (NYSE:MRK) announced that the Phase 3 KEYNOTE-689 trial of Keytruda (pembrolizumab), as a perioperative treatment for patients newly diagnosed with stage III or IVA, ...
Merck is strong in cash and balance sheet and will have continued growth in their highest-margin product while being greatly ...
Merck’s cancer drug giant Keytruda has helped the Big Pharma top how oncologists see cancer drug makers, but no one company is dominating the field. That’s according to the latest report from analysts ...
Goldman Sachs analyst Chris Shibutani has reiterated their bullish stance on MRK stock, giving a Buy rating today. Chris Shibutani has given his Buy rating due to a combination of factors surrounding ...
8d
Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook
Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.
Summit Therapeutics' ivonescimab shows promise potential in two phase 3 trials for lung cancer. Stifel analyst sees an opportunity for two updates from Summit Therapeutics' Chinese partner Akeso in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback